Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phendimetrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phendimetrazine SCHEMBL29353044 | 1.00 | HTR1A (0.75) | HTR1AKDM4EBLMALOX15SLC6A2 | |
| Phendimetrazine SCHEMBL29554688 | 1.00 | HTR1A (0.75) | HTR1AKDM4EBLMALOX15SLC6A2 | |
| Phendimetrazine SCHEMBL160376 | 1.00 | HTR1A (0.75) | HTR1AKDM4EBLMALOX15SLC6A2 | |
| Phendimetrazine SCHEMBL160375 | 1.00 | HTR1A (0.75) | HTR1AKDM4EBLMALOX15SLC6A2 | |
| Phendimetrazine SCHEMBL10613088 | 0.99 | HTR1A (0.73) | HTR1AKDM4EBLMALOX15SLC6A2 | |
| Phendimetrazine SCHEMBL21603017 | 0.88 | HTR1A (0.57) | HTR1AKDM4EBLMALOX15CYP2D6 | |
| Phendimetrazine SCHEMBL15064942 | 0.87 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL49481 | 0.87 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL344020 | 0.87 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL598950 | 0.87 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258778-B2 | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like | CHRONO THERAPEUTICS INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10258738-B2 | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like | CHRONO THERAPEUTICS INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170224911-A1 | BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY FOR LONGEVITY, ANTI-AGING, FATIGUE MANAGEMENT, OBESITY, WEIGHT LOSS, WEIGHT MANAGEMENT, DELIVERY OF NUTRACEUTICALS, AND THE TREATMENT OF HYPERGLYCEMIA, ALZHEIMER'S DISEASE, SLEEP DISORDERS, PARKINSON'S DISEASE, AIDS, EPILEPSY, ATTENTION DEFICIT DISORDER, NICOTINE ADDICTION, CANCER, HEADACHE AND PAIN CONTROL, ASTHMA, ANGINA, HYPERTENSION, DEPRESSION, COLD, FLU AND THE LIKE | MORNINGSIDE VENTURE INVESTMENTS LIMITED | 2017-08-10 | — | — | US | disclosed |
| US-20170182299-A1 | BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY FOR LONGEVITY, ANTI-AGING, FATIGUE MANAGEMENT, OBESITY, WEIGHT LOSS, WEIGHT MANAGEMENT, DELIVERY OF NUTRACEUTICALS, AND THE TREATMENT OF HYPERGLYCEMIA, ALZHEIMER'S DISEASE, SLEEP DISORDERS, PARKINSON'S DISEASE, AIDS, EPILEPSY, ATTENTION DEFICIT DISORDER, NICOTINE ADDICTION, CANCER, HEADACHE, AND PAIN CONTROL, ASTHMA, ANGINA, HYPERTENSION, DEPRESSION, COLD, FLUE AND THE LIKE | MORNINGSIDE VENTURE INVESTMENTS LIMITED | 2017-06-29 | — | — | US | disclosed |
| US-20140364363-A1 | GLYPICAN-4 BASED COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING INSULIN RESISTANCE | JOSLIN DIABETES CENTER, INC. | 2014-12-11 | — | — | US | disclosed |
| EP-2797619-A1 | GLYPICAN-4 BASED COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING INSULIN RESISTANCE | Joslin Diabetes Center, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013102209-A1 | GLYPICAN-4 BASED COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING INSULIN RESISTANCE | JOSLIN DIABETES CENTER, INC. (US) | 2013-07-04 | — | — | WO | disclosed |